Further processing options
online resource

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus

Bibliographic Details
Journal Title: Vascular Medicine
Authors and Corporations: Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J.
In: Vascular Medicine, 12, 2007, 4, p. 311-318
Type of Resource: E-Article
Language: English
published:
SAGE Publications
Subjects:
finc.format ElectronicArticle
finc.mega_collection SAGE Publications (CrossRef)
finc.id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xMzU4ODYzeDA3MDg0MjAw
finc.source_id 49
ris.type EJOUR
rft.atitle Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
rft.epage 318
rft.genre article
rft.issn 1358-863X
1477-0377
rft.issue 4
rft.jtitle Vascular Medicine
rft.tpages 8
rft.pages 311-318
rft.pub SAGE Publications
rft.date 2007-11-01
x.date 2007-11-01T00:00:00Z
rft.spage 311
rft.volume 12
abstract <jats:p> We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p &lt; 0.0001) and HbA1c (p &lt; 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p &lt; 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p &lt; 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress. </jats:p>
authors Array ( [rft.aulast] => Kelly [rft.aufirst] => Aaron S. )
Array ( [rft.aulast] => Thelen [rft.aufirst] => Andrea M. )
Array ( [rft.aulast] => Kaiser [rft.aufirst] => Daniel R. )
Array ( [rft.aulast] => Gonzalez-Campoy [rft.aufirst] => J. Michael )
Array ( [rft.aulast] => Bank [rft.aufirst] => Alan J. )
doi 10.1177/1358863x07084200
languages eng
url http://dx.doi.org/10.1177/1358863x07084200
version 0.9
x.subjects Cardiology and Cardiovascular Medicine
x.type journal-article
x.oa 1
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fwww.hszg.de%3Agenerator&rft.title=Rosiglitazone+improves+endothelial+function+and+inflammation+but+not+asymmetric+dimethylarginine+or+oxidative+stress+in+patients+with+type+2+diabetes+mellitus&rft.date=2007-11-01&genre=article&issn=1477-0377&volume=12&issue=4&spage=311&epage=318&pages=311-318&jtitle=Vascular+Medicine&atitle=Rosiglitazone+improves+endothelial+function+and+inflammation+but+not+asymmetric+dimethylarginine+or+oxidative+stress+in+patients+with+type+2+diabetes+mellitus&aulast=Bank&aufirst=Alan+J.&rft_id=info%3Adoi%2F10.1177%2F1358863x07084200&rft.language%5B0%5D=eng
SOLR
_version_ 1748578439048200209
access_facet Electronic Resources
author Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J.
author_facet Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J., Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J.
author_sort kelly, aaron s.
branch_nrw Electronic Resources
container_issue 4
container_start_page 311
container_title Vascular Medicine
container_volume 12
description <jats:p> We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p &lt; 0.0001) and HbA1c (p &lt; 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p &lt; 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p &lt; 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress. </jats:p>
doi_str_mv 10.1177/1358863x07084200
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE3Ny8xMzU4ODYzeDA3MDg0MjAw
imprint SAGE Publications, 2007
imprint_str_mv SAGE Publications, 2007
institution DE-Gla1, DE-15, DE-105, DE-Ch1, DE-Zwi2, DE-Bn3, DE-D275, DE-D161, DE-L229, DE-Zi4, DE-Pl11, DE-Brt1, DE-Rs1, DE-82, DE-14
issn 1358-863X, 1477-0377
issn_str_mv 1358-863X, 1477-0377
language English
last_indexed 2022-11-04T15:05:47.195Z
match_str kelly:2007:rosiglitazoneimprovesendothelialfunctionandinflammationbutnotasymmetricdimethylarginineoroxidativestressinpatientswithtype2diabetesmellitus:
mega_collection SAGE Publications (CrossRef)
physical 311-318
publishDate 2007
publishDateSort 2007
publisher SAGE Publications
recordtype ai
score 18,68584
series Vascular Medicine
source_id 49
spelling Kelly, Aaron S. Thelen, Andrea M. Kaiser, Daniel R. Gonzalez-Campoy, J. Michael Bank, Alan J. 1358-863X 1477-0377 SAGE Publications Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1177/1358863x07084200 <jats:p> We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p &lt; 0.0001) and HbA1c (p &lt; 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p &lt; 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p &lt; 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress. </jats:p> Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus Vascular Medicine
spellingShingle Kelly, Aaron S., Thelen, Andrea M., Kaiser, Daniel R., Gonzalez-Campoy, J. Michael, Bank, Alan J., Vascular Medicine, Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus, Cardiology and Cardiovascular Medicine
title Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
title_full Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
title_fullStr Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
title_full_unstemmed Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
title_short Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
title_sort rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
topic Cardiology and Cardiovascular Medicine
url http://dx.doi.org/10.1177/1358863x07084200